Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.54 |
| ▸ | PI4KA | P42356 | 2/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665392 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1665301 | 0.81 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| Bromide SCHEMBL9778439 | 0.79 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778362 | 0.79 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778392 | 0.79 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778422 | 0.79 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778348 | 0.79 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| SCHEMBL4815870 | 0.79 | ADORA2A (0.71) | ADORA2AADORA1PIK3CDKDREGFR | |
| SCHEMBL8584781 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28115748 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2847329-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | Moderna Therapeutics, Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014092572-A1 | IMPROVED METHODS FOR CANCER TREATMENT WITH A GENOTOXIC AGENT | UNIVERSITEIT LEIDEN (NL) | 2014-06-19 | — | — | WO | disclosed |
| WO-2013151669-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-2281043-B1 | IMPROVED TLR3 AGONIST COMPOSITIONS | INNATE PHARMA (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2003027327-A1 | ANTISENSE MODULATION OF INTERLEUKIN 8 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | ADORA2A 2677/4885ADORA1 2841/4885PI4KA 1802/4885 |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885PI4KA 5/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | ADORA2A 469/4885ADORA1 192/4885PI4KA 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.